deucravacitinib

Contraindicated in:

Hypersensitivity;
Active or serious infection (including tuberculosis [TB] and hepatitis B/C);
Severe hepatic impairment.

Use Cautiously in:

Chronic or recurrent infection, exposure to tuberculosis, history of opportunistic infection, underlying conditions that predispose to infection;
Malignancy (other than successfully treated non-melanoma skin cancer);
OB: Safety not established in pregnancy;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: acne

GI: ↑liver enzymes, mouth ulcers

Metab: hypertriglyceridemia

MS: ↑creatine kinase, RHABDOMYOLYSIS

Misc: infection, HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA), MALIGNANCY (INCLUDING LYMPHOMA)

Interactions ⬆ ⬇

Drug-drug:

Avoid concurrent use with live vaccines.

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

PO (Adults ): 6 mg once daily.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Acts as a inhibitor of tyrosine kinase 2. Its exact mechanism for effect in plaque psoriasis is unknown.

Therapeutic effects:

Decreased formation and spread of plaques.

Classifications ⬆ ⬇

Therapeutic Classification: antipsoriatics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed (99%) following oral administration.

Distribution: Extensively distributed to tissues.

Protein Binding: 82–90%.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP1A2 isoenzyme to form an active metabolite (BMT-153261). Also metabolized by CYP2B6, CYP2D6, carboxylesterase 2, and UGT1A9. 26% and 13% excreted in feces and urine, respectively, as unchanged drug.

Half-Life: 10 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	2–3 hr	24 hr

Patient/Family Teaching ⬆ ⬇

Instruct patient to take deucravacitinib as directed. Advise patient to read Medication Guide before starting therapy and with each Rx refill in case of changes.
Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
Advise patient to avoid live vaccines during therapy.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Inform patients that medication may increase their risk of developing malignancies, including lymphomas.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. If pregnancy occurs, report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.
Encourage patient to maintain follow-up lab tests to monitor blood levels.

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇